Related Experiment Video
Updated: Oct 16, 2025

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
REDD1 deletion attenuates cancer cachexia in mice
Brian A Hain1,2, Haifang Xu1, Ashley M VanCleave1
1Department of Cellular and Molecular Physiology, The Penn State College of Medicine, Hershey, Pennsylvania.
Abstract:
Cancer cachexia is a wasting disorder associated with advanced cancer that contributes to mortality. Cachexia is characterized by involuntary loss of body weight and muscle weakness that affects physical function. Regulated in DNA damage and development 1 (REDD1) is a stress-response protein that is transcriptionally upregulated in muscle during wasting conditions and inhibits mechanistic target of rapamycin complex 1 (mTORC1). C2C12 myotubes treated with Lewis lung carcinoma (LLC)-conditioned media increased REDD1 mRNA expression and decreased myotube diameter. To investigate the role of REDD1 in cancer cachexia, we inoculated 12-wk-old male wild-type or global REDD1 knockout (REDD1 KO) mice with LLC cells and euthanized 28 days later. Wild-type mice had increased skeletal muscle REDD1 expression, and REDD1 deletion prevented loss of body weight and lean tissue mass but not fat mass. We found that REDD1 deletion attenuated loss of individual muscle weights and loss of myofiber cross-sectional area. We measured markers of the Akt/mTORC1 pathway and found that, unlike wild-type mice, phosphorylation of both Akt and 4E-BP1 was maintained in the muscle of REDD1 KO mice after LLC inoculation, suggesting that loss of REDD1 is beneficial in maintaining mTORC1 activity in mice with cancer cachexia. We measured Foxo3a phosphorylation as a marker of the ubiquitin proteasome pathway and autophagy and found that REDD1 deletion prevented dephosphorylation of Foxo3a in muscles from cachectic mice. Our data provide evidence that REDD1 plays an important role in cancer cachexia through the regulation of both protein synthesis and protein degradation pathways.NEW & NOTEWORTHY Cancer cachexia is a debilitating and lethal consequence of many advanced cancers. REDD1, a negative regulator of mTORC1 activity, is an emerging target in cachexia. Our data show that skeletal muscle REDD1 expression is increased in LLC-induced cancer cachexia. Mice lacking REDD1 have attenuated skeletal muscle atrophy that is likely due to maintaining both protein synthesis and inhibiting protein degradation.
Insights
Regulated in DNA damage and development 1 (REDD1) protein worsens cancer cachexia by increasing muscle wasting. Deleting REDD1 in mice prevented weight loss and muscle atrophy, offering a potential therapeutic target for this condition.
Area of Science:
- Muscle wasting disorders
- Cancer biology
- Molecular signaling pathways
Background:
- Cancer cachexia is a wasting disorder causing mortality in advanced cancer patients.
- It involves involuntary weight loss and muscle weakness, impairing physical function.
- Regulated in DNA damage and development 1 (REDD1) is a stress protein upregulated in muscle during wasting, inhibiting mTORC1.
Purpose of the Study:
- To investigate the role of REDD1 in cancer cachexia.
- To determine if REDD1 deletion impacts body weight, lean mass, and muscle atrophy.
- To analyze the effects of REDD1 deletion on Akt/mTORC1 and ubiquitin proteasome pathways.
Main Methods:
- Inoculated wild-type and REDD1 knockout mice with Lewis lung carcinoma (LLC) cells.
- Assessed body weight, lean tissue mass, fat mass, and individual muscle weights.
- Measured myofiber cross-sectional area, Akt/mTORC1 pathway markers (p-Akt, p-4E-BP1), and Foxo3a phosphorylation.
Main Results:
- Wild-type mice showed increased skeletal muscle REDD1 expression and cachexia.
- REDD1 deletion prevented body weight and lean tissue loss, but not fat mass.
- REDD1 knockout mice exhibited attenuated muscle atrophy, maintained Akt/mTORC1 activity, and prevented Foxo3a dephosphorylation.
Conclusions:
- REDD1 plays a significant role in cancer cachexia development.
- REDD1 deletion mitigates skeletal muscle atrophy by preserving protein synthesis and inhibiting protein degradation.
- Targeting REDD1 may be a therapeutic strategy for managing cancer cachexia.

